Skip to content

INTERCEPT PHARMACEUTICALS, INC.

Delisted

CIK 1270073fmd_1YBYATRR2118WJG5HWVVP2P648Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2008 to Sep 30, 2023, 54 periods

Latest annual · FY2022

Millions
Total revenues
286
Gross profit
285
Operating income
(68)
Net income
222
Free cash flow
(27)

Latest quarter · Q3 FY2023

Millions
Total revenues
89
Gross profit
89
Operating income
(5)
Net income
(3)
Free cash flow
17
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2019 to FY2022
+4.3%
Revenue, 5 yearsFY2017 to FY2022
+16.9%
Net income, 5 yearsFY2017 to FY2022
n/m

INTERCEPT PHARMACEUTICALS, INC. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2022FY2021ChangeSource
Revenue$285.7 million$260.8 million+9.6%10-K 2023-03-02 · proof
Gross profit$284.7 million$259.5 million+9.7%10-K 2023-03-02 · proof
Operating income-$68.2 million-$100.4 million10-K 2023-03-02 · proof
Net income$221.8 million-$91.4 million10-K 2023-03-02 · proof
Cash from operating activities-$26.8 million-$41.1 million10-K 2023-03-02 · proof
Free cash flow-$27.3 million-$41.5 million10-K 2023-03-02 · proof
Total assets$553.7 million$527 million+5.1%10-K 2023-03-02 · proof
Total liabilities$460.6 million$711 million-35.2%10-K 2023-03-02 · proof
Cash and cash equivalents$50.5 million$84.7 million-40.4%10-K 2023-03-02 · proof
Total debt$332.7 million$539.8 million-38.4%10-K 2023-03-02 · proof
What was INTERCEPT PHARMACEUTICALS, INC.'s revenue in fiscal 2022?
INTERCEPT PHARMACEUTICALS, INC. reported revenue of $285.7 million for fiscal 2022 (the year ended Dec 31, 2022), against $260.8 million the year before (+9.6%). Source: the 10-K filed with the SEC on Mar 2, 2023. SEC
What was INTERCEPT PHARMACEUTICALS, INC.'s gross profit in fiscal 2022?
INTERCEPT PHARMACEUTICALS, INC. reported gross profit of $284.7 million for fiscal 2022 (the year ended Dec 31, 2022), against $259.5 million the year before (+9.7%). Source: the 10-K filed with the SEC on Mar 2, 2023. SEC
What was INTERCEPT PHARMACEUTICALS, INC.'s operating income in fiscal 2022?
INTERCEPT PHARMACEUTICALS, INC. reported operating income of -$68.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$100.4 million the year before. Source: the 10-K filed with the SEC on Mar 2, 2023. SEC
What was INTERCEPT PHARMACEUTICALS, INC.'s net income in fiscal 2022?
INTERCEPT PHARMACEUTICALS, INC. reported net income of $221.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -$91.4 million the year before. Source: the 10-K filed with the SEC on Mar 2, 2023. SEC
What was INTERCEPT PHARMACEUTICALS, INC.'s cash from operating activities in fiscal 2022?
INTERCEPT PHARMACEUTICALS, INC. reported cash from operating activities of -$26.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -$41.1 million the year before. Source: the 10-K filed with the SEC on Mar 2, 2023. SEC
What was INTERCEPT PHARMACEUTICALS, INC.'s free cash flow in fiscal 2022?
INTERCEPT PHARMACEUTICALS, INC. reported free cash flow of -$27.3 million for fiscal 2022 (the year ended Dec 31, 2022), against -$41.5 million the year before. Source: the 10-K filed with the SEC on Mar 2, 2023. SEC
What are INTERCEPT PHARMACEUTICALS, INC.'s total assets?
As of Dec 31, 2022, INTERCEPT PHARMACEUTICALS, INC. reported total assets of $553.7 million, against $527 million a year earlier (+5.1%). Source: the 10-K filed with the SEC on Mar 2, 2023. SEC
What are INTERCEPT PHARMACEUTICALS, INC.'s total liabilities?
As of Dec 31, 2022, INTERCEPT PHARMACEUTICALS, INC. reported total liabilities of $460.6 million, against $711 million a year earlier (-35.2%). Source: the 10-K filed with the SEC on Mar 2, 2023. SEC
What are INTERCEPT PHARMACEUTICALS, INC.'s cash and cash equivalents?
As of Dec 31, 2022, INTERCEPT PHARMACEUTICALS, INC. reported cash and cash equivalents of $50.5 million, against $84.7 million a year earlier (-40.4%). Source: the 10-K filed with the SEC on Mar 2, 2023. SEC
What is INTERCEPT PHARMACEUTICALS, INC.'s total debt?
As of Dec 31, 2022, INTERCEPT PHARMACEUTICALS, INC. reported total debt of $332.7 million, against $539.8 million a year earlier (-38.4%). Source: the 10-K filed with the SEC on Mar 2, 2023. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1270073&period_type=annual&limit=5"

Information only, not investment advice.